Despite the advisory committee’s conclusions, no official action has been taken by the FDA as of late October 2023. If the company proposes a change within the availability of phenylephrine, consumers shall be asked to weigh in previous to a last ruling. Additional studies since then confirmed no difference in efficacy between phenylephrine and a placebo, likely…